Back to results
US 12,606,613 B2Granted
Humanized anti-C5a antibodies
AssigneeInflaRx GmbH
InventorsRenfeng Guo, Niels C. Riedemann
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies that specifically bind to a conformational epitope of human C5a. The invention particularly relates to humanized anti-C5a antibodies. The antibodies described herein are useful as active agents in pharmaceutical compositions. The antibodies and pharmaceutical compositions are especially useful for the treatment and prevention of diseases or disorders involving pathological C5a activity.
Claims9
An antibody or an antigen-binding fragment thereof that specifically binds to human C5, comprising a heavy chain variable domain (VH) and a light chain variable domain (VL),
- a) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 8 (VH2) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 15 (Vκ3);
- b) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 8 (VH2) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 16 (Vκ4);
- c) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 9 (VH3) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 14 (Vκ2);
- d) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 9 (VH3) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 16 (Vκ4);
- e) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 10 (VH4) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 13 (Vκ1);
- f) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 10 (VH4) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 14 (Vκ2);
- g) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 10 (VH4) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 15 (Vκ3);
- h) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 10 (VH4) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 16 (Vκ4);
- i) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 11 (VH5) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 13 (Vκ1);
- j) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 11 (VH5) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 14 (Vκ2);
- k) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 11 (VH5) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 15 (Vκ3);
- or
- l) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 11 (VH5) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO:
- 16 (Vκ4).
34 more elements
Dependencies are inferred from the claim text.